

AMENDMENTS TO THE SPECIFICATION

Please insert the following paragraph on page 1, between lines 3 and 4:

CROSS-REFERENCE TO RELATED APPLICATIONS

The present application is a National Stage (371) of PCT/JP00/02127, filed on March 31, 2000, which claims priority to JP 11/96073, filed on April 2, 1999.

Please amend the paragraph beginning on page 9, line 21 as follows:

Fig. 3 shows results of analysis by reverse phase HPLC, of refolded AS1051-WT (Fig. 3a) and AS1051-Ala (Fig. 3b) samples before dialysis (a) and after dialysis (b). Time is represented on the horizontal axis and absorbance (216 nm), i.e., the amount of dissolved proteins is represented on the vertical axis.

Please amend the paragraph beginning on page 10, line 3 as follows:

Fig. 6 Fig. 6a is a reverse phase liquid chromatogram of the AS1051 protein in which the cysteine residue at position 81 was replaced with an alanine residue (AS1051-Ala) after digestion with lysyl endopeptidase. Fig. 6b is a reverse phase liquid chromatogram of the polyethylene-glycolated AS1051 (AS1051-PEG) after digestion with lysyl endopeptidase. The polypeptide fragments in Fig. 6 can be found in the Sequence Listing as follows:  
sequence 1 = residues 41-43 of SEQ ID NO: 5; sequence 2 = residues 145-149 of SEQ ID NO: 5; sequence 3 = residues 24-40 of SEQ ID NO: 5; sequence 4 (top) = residues 85-100 of SEQ ID NO: 5 and sequence 4 (bottom) = residues 44-60 of SEQ ID NO: 5; sequence 5 (top) = residues 133-144 of SEQ ID NO: 5 and sequence 5 (bottom) = residues 101-132 of SEQ ID NO: 5; sequence 6 = residues 61-84 of SEQ ID NO: 5.

Please amend the paragraph beginning on page 10, line 6 as follows:

Fig. 7 shows inhibitory activities of AS1051-Ala (Fig. 7a) and AS1051-PEG (Fig. 7b  
and Fig. 7c) on ristocetin aggregation.

Please amend the paragraph beginning on page 10, line 8 as follows:

Fig. 8 shows activities of AS1051-Ala and AS1051-PEG for inhibiting binding of  
fixed platelets and vWF. In Fig. 8a the results are shown for ristocetin-induced vWF  
binding, while in Fig. 8b the results are shown for ristocetin-induced vWF binding.